Enzyme structure opens the door to HIV and Hepatitis C treatment: New study
The findings open the door to the development of new drugs to combat these deadly viruses that infect more than 180 million people worldwide.
The team of international scientists led by Associate Professor Spencer Williams from the University of Melbourne’s Bio21 Institute and Professor Gideon Davies from the University of York in the UK, studied bacterial endomannosidase as a model for the same human enzyme and successfully determined the three dimensional structure of the enzyme using state of the art synchrotron technology.
Dr Williams said that knowing the structure of the enzyme revealed details on how viruses hijack human enzymes using them to replicate and cause infection.
“If we understand how the viruses use our enzymes, we can develop inhibitors that block the pathway they require, opening the door to drug developments,” he said.
“In the past the problem has been that this group of viruses including HIV, Hepatitis C, Dengue Fever and West Nile virus, are able to bypass the main pathway if inhibited and replicate via a second pathway using this enzyme. Thus for a treatment to be effective, both pathways need to be blocked.
“It was already known how to block the main pathway for these viruses but until now, this endomannosidase bypass pathway has proved a considerable challenge to study.
“Combining international resources and expertise, we were able to determine the endomannosidae structure and this has revealed how we can block the bypass route, stopping the viruses from hijacking human enzymes.”
Professor Davies from the University of York said that the team hopes that the work will lead beyond viruses and will point the way towards similar treatments for other diseases including cancer.
The study is published in the international journal, Proceedings of the National Academy of Sciences (PNAS) this week.
HealthCanal.com
More...
